Buspirone induced prolactin release in mania

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Serotonin 5HT1A receptors are implicated in mood regulation.
• Buspirone is a 5HT1A receptor agonist used to assess receptor function.
• Mania involves complex neurobiological dysregulation.

Purpose of the Study:

• To investigate the role of 5HT1A receptors in mania using a buspirone challenge test.
• To assess prolactin response to buspirone in manic patients compared to healthy controls.
• To evaluate the effect of lithium treatment on prolactin response and its correlation with manic symptom severity.

Main Methods:

• Buspirone challenge test administered to 11 manic patients and 11 healthy controls.
• Measurement of prolactin levels before and after buspirone administration.
• Six manic patients received lithium treatment for 3 weeks, followed by a repeat buspirone challenge test.
• Assessment of manic symptom severity using clinical scales.

Main Results:

• No significant difference in prolactin response to buspirone challenge was observed between manic patients and healthy controls.
• No correlation was found between the change in prolactin levels (delta prolactin) and the severity of manic symptoms.
• Lithium treatment significantly reduced delta prolactin levels, but this reduction did not correlate with changes in symptom severity.

Conclusions:

• The findings suggest that 5HT1A receptor function, as assessed by prolactin response to buspirone, is unlikely to be directly involved in the pathophysiology of mania.
• Lithium's effect on prolactin response does not appear to be directly linked to its therapeutic efficacy in reducing manic symptoms.
• Further research is needed to elucidate the neurobiological underpinnings of mania.